Otto S. Hoekstra

Amsterdam University Medical Centers — Netherlands

Medicine · Health Sciences

82h-index34.3kcitations560works0.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(275), Radiomics and Machine Learning in Medical Imaging(228), Lung Cancer Diagnosis and Treatment(69), Radiopharmaceutical Chemistry and Applications(68), Lymphoma Diagnosis and Treatment(66)

Publications557 total

Supplement LASSO from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2025Open Access

Supplementary Data1 from Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

2025Open Access

Supplementary Figure S2 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure S3 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2025Open Access

Supplementary Figure S1 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2025Open Access

Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer

Clinical Cancer Research·2025

Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors

1 cited

Scientific Reports·2025· 1 citedOpen Access

412 | IMPROVING THE PREDICTIVE VALUE OF END‐OF‐TREATMENT PET/CT IN DIFFUSE LARGE B‐CELL LYMPHOMA

Hematological Oncology·2025Open Access

Early [18F]FDG PET/CT response evaluation after a single dose of anti-EGFR therapy as a predictive biomarker for treatment benefit in patients with advanced colorectal cancer.

Journal of Clinical Oncology·2024

An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients

30 cited

Scientific Reports·2023· 30 citedOpen Access

Supplementary Figure S2 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2023Open Access

Supplementary Figure S1 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2023Open Access

Supplement LASSO from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2023Open Access

Supplementary Data1 from Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

2023Open Access

Supplementary Data1 from Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

2023Open Access

Data from Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

2023Open Access

Supplementary Figure S2 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2023Open Access

Supplementary Figure S1 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2023Open Access

Data from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

2023Open Access

Data from Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

2023Open Access

page 1 of 28Next →

Frequent Co-authors

Ronald Boellaard(18), Adriaan A. Lammertsma(12), Egbert F. Smit(11), Josée M. Zijlstra(10), Emile F.I. Comans(10), C. Hoekstra(9), Sigrid Stroobants(8), G. J. J. Teule(7), Jan Pruim(6), Harm van Tinteren(6), Pieter E. Postmus(6), Wim J.G. Oyen(5), Lawrence H. Schwartz(5), Lalitha Shankar(5), Maarten Boers(5), Sally F. Barrington(4), Wolfgang Weber(4), Eric P. Visser(4), Elisabeth G.E. de Vries(4), Wendy Hayes(4)